Actelion Awards Grants to 2013 ENTELLIGENCE™ Young Investigators for Research in Pulmonary Arterial Hypertension (PAH) Philadelphia, Pennsylvania – June 4, 2013:
Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in PAH. Each researcher will receive a 12-month mentored grant of up to $100,000 in support, funded through the Actelion-supported ENTELLIGENCE program. The announcement was made at a recent awards luncheon during which the four recipients of the 2013 awards gave an overview of their proposed work.

“I am extremely proud of the accomplishments of the ENTELLIGENCE Young Investigators Program. Award recipients, together with their mentors, today presented their scientific proposals while being recognized for their promising research at the annual ENTELLIGENCE Awards Program Ceremony,” said Dr. Ronald J. Oudiz, ENTELLIGENCE Steering Committee Chairman and Director of the Liu Center for Pulmonary Hypertension at the LA Biomedical Research Institute at Harbor-UCLA Medical Center. “For the past 8 award cycles, ENTELLIGENCE, with nearly $3.5 million in funding, has supported innovative basic, translational, and clinical research that has fostered the development of 42 young investigators’ careers in pulmonary vascular research. During this time, the awardees’ research findings have been published in peer-reviewed journals and we have even seen some previous awardees return later to act as mentors for new young investigators. We have thus achieved several important ENTELLIGENCE milestones and very much look forward to next year’s program,” Oudiz said.

Attendees of the Awards Reception included Dr. Martine Clozel, Senior Vice President and Chief Scientific Officer at Actelion (who, with her husband, Dr. Jean-Paul Clozel, had the vision more than 20 years ago that endothelin antagonism would be an effective therapeutic modality in PAH), other representatives from Actelion, and Rino Aldrighetti, President of the Pulmonary Hypertension Association.

The 2013 award winners, their mentors, and the supported projects are:

**Harry Karmouty-Quintana, PhD**
Assistant Professor
University of Texas-Health Science Center at Houston
Houston, Texas
Mentor: Michael R. Blackburn, PhD
Project Title: The Role of Hyaluronan in Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis (IPF)

**Michael L. O’Byrne, MD**
Fellow Physician, Division of Cardiology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania
Co-Investigators: Brian D. Hanna, MD, PhD; Steven M. Kawut, MD, MS; Russell T. Shinohara, PhD
Mentor: Jonathan J. Rome, MD
Project Title: Adverse Outcomes Associated with Cardiac Catheterization in Children with Pulmonary Arterial Hypertension
Tien Peng, MD  
Instructor, Pulmonary, Allergy and Critical Care Division  
Hospital of the University of Pennsylvania  
Philadelphia, Pennsylvania  
Mentor: Edward Morrisey, PhD  
Project Title: *The Role of Sonic Hedgehog (Shh) Signaling in Pulmonary Arterial Hypertension*

Keivan Zandinejad, MD  
Pulmonary/Critical Care and Sleep Fellow  
Case Western Reserve University  
Cleveland, Ohio  
Mentor: Jonathan S. Stamler, MD  
Project Title: *S-Nitrosylation Therapy to Treat Hypoxia-Induced Pulmonary Arterial Hypertension*

About ENTELLIGENCE  
The ENTELLIGENCE program was established by Actelion in 2005 to support basic science, translational, and clinical research in the field of cardiopulmonary medicine. The program is part of Actelion’s ongoing commitment to advance quality medical care and to enhance patients’ lives by supporting research that contributes to understanding and treating pulmonary vascular disease through research grants to young investigators. ENTELLIGENCE is led by a Steering Committee comprised of leaders in the field of pulmonary hypertension.

The next ENTELLIGENCE grant award cycle begins on September 19, 2013. For more information regarding the Young Investigators Award Program, please visit www.ENTELLIGENCEMD.org. For further information, please contact: Medtelligence, LLC (jfreeman@medtelligence.net).

From left to right: Keivan Zandinejad, MD, Tien Peng, MD, Martine Clozel, MD, Michael O’Byrne, MD, and Harry Karmouty-Quintana, PhD
From left to right: Michael O’Byrne, MD, Tien Peng, MD, Ronald Oudiz, MD, Keivan Zandinejad, MD, and Harry Karmouty-Quintana, PhD

From left to right: Evangelos Michelakis, MD, Adaani Frost, MD, Michael O’Byrne, MD, Harrison Farber, MD, Tien Peng, MD, Ronald Oudiz, MD, Harold Palevsky, MD, Keivan Zandinejad, MD, Michael Blackburn, PhD, and Harry Karmouty-Quintana, PhD